A detailed history of Victory Capital Management Inc transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Victory Capital Management Inc holds 411,906 shares of APLS stock, worth $11.6 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
411,906
Previous 461,866 10.82%
Holding current value
$11.6 Million
Previous $17.7 Million 32.95%
% of portfolio
0.01%
Previous 0.02%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

SELL
$28.84 - $41.15 $1.44 Million - $2.06 Million
-49,960 Reduced 10.82%
411,906 $11.9 Million
Q2 2024

Aug 05, 2024

SELL
$38.07 - $59.71 $1.14 Million - $1.79 Million
-30,031 Reduced 6.11%
461,866 $17.7 Million
Q1 2024

May 03, 2024

SELL
$55.39 - $72.47 $6.89 Million - $9.01 Million
-124,375 Reduced 20.18%
491,897 $28.9 Million
Q4 2023

Feb 05, 2024

SELL
$37.14 - $64.82 $4.54 Million - $7.92 Million
-122,239 Reduced 16.55%
616,272 $36.9 Million
Q3 2023

Nov 06, 2023

BUY
$23.65 - $89.22 $7.98 Million - $30.1 Million
337,554 Added 84.19%
738,511 $28.1 Million
Q2 2023

Jul 27, 2023

SELL
$76.68 - $93.31 $12.4 Million - $15 Million
-161,212 Reduced 28.68%
400,957 $36.5 Million
Q1 2023

May 02, 2023

BUY
$46.59 - $66.96 $6.13 Million - $8.81 Million
131,618 Added 30.57%
562,169 $37.1 Million
Q4 2022

Feb 10, 2023

BUY
$43.24 - $61.04 $4,021 - $5,676
93 Added 0.02%
430,551 $22.3 Million
Q4 2022

Feb 09, 2023

SELL
$43.24 - $61.04 $10.5 Million - $14.8 Million
-242,593 Reduced 36.04%
430,458 $22.3 Million
Q3 2022

Nov 02, 2022

SELL
$44.76 - $69.66 $1.12 Million - $1.75 Million
-25,120 Reduced 3.6%
673,051 $46 Million
Q2 2022

Aug 01, 2022

SELL
$35.07 - $59.21 $22 Million - $37.1 Million
-626,793 Reduced 47.31%
698,171 $31.6 Million
Q1 2022

May 04, 2022

SELL
$35.46 - $54.12 $8.55 Million - $13 Million
-241,013 Reduced 15.39%
1,324,964 $67.2 Million
Q4 2021

Feb 07, 2022

SELL
$30.74 - $49.16 $6.3 Million - $10.1 Million
-204,830 Reduced 11.57%
1,565,977 $74 Million
Q3 2021

Nov 02, 2021

BUY
$31.4 - $69.84 $3.6 Million - $8 Million
114,519 Added 6.91%
1,770,807 $58.4 Million
Q2 2021

Aug 03, 2021

SELL
$40.9 - $64.9 $11.3 Million - $18 Million
-277,492 Reduced 14.35%
1,656,288 $105 Million
Q1 2021

May 04, 2021

BUY
$40.8 - $57.39 $971,162 - $1.37 Million
23,803 Added 1.25%
1,933,780 $83 Million
Q4 2020

Feb 01, 2021

SELL
$30.79 - $57.2 $7.25 Million - $13.5 Million
-235,485 Reduced 10.98%
1,909,977 $109 Million
Q3 2020

Nov 09, 2020

BUY
$25.89 - $33.65 $4.68 Million - $6.09 Million
180,917 Added 9.21%
2,145,462 $64.7 Million
Q2 2020

Aug 07, 2020

BUY
$24.8 - $38.49 $2.43 Million - $3.78 Million
98,130 Added 5.26%
1,964,545 $64.2 Million
Q1 2020

May 04, 2020

SELL
$17.91 - $44.33 $5.43 Million - $13.4 Million
-302,934 Reduced 13.96%
1,866,415 $50 Million
Q4 2019

Feb 06, 2020

SELL
$22.1 - $30.8 $3.29 Million - $4.58 Million
-148,720 Reduced 6.42%
2,169,349 $66.4 Million
Q4 2019

Feb 04, 2020

BUY
$22.1 - $30.8 $11.4 Million - $15.9 Million
516,627 Added 28.68%
2,318,069 $95.3 Million
Q3 2019

Nov 12, 2019

BUY
$24.09 - $32.18 $3.35 Million - $4.48 Million
139,239 Added 8.38%
1,801,442 $43.4 Million
Q2 2019

Aug 15, 2019

SELL
$18.0 - $25.34 $476,280 - $670,496
-26,460 Reduced 1.57%
1,662,203 $42.1 Million
Q1 2019

May 03, 2019

BUY
$12.81 - $19.82 $3.85 Million - $5.96 Million
300,900 Added 21.68%
1,688,663 $32.9 Million
Q4 2018

Feb 05, 2019

BUY
$11.47 - $18.71 $458,914 - $748,587
40,010 Added 2.97%
1,387,763 $18.3 Million
Q3 2018

Nov 01, 2018

BUY
$16.57 - $21.03 $6.88 Million - $8.73 Million
415,000 Added 44.49%
1,347,753 $24 Million
Q2 2018

Aug 02, 2018

BUY
$19.63 - $30.0 $11 Million - $16.8 Million
559,913 Added 150.18%
932,753 $20.5 Million
Q1 2018

May 04, 2018

BUY
$14.01 - $26.02 $5.22 Million - $9.7 Million
372,840 New
372,840 $8.24 Million

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.08B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Victory Capital Management Inc Portfolio

Follow Victory Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.